Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Colorectal Neoplasms

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    October 2021
  1. KONUKIEWITZ B, Schmitt M, Silva M, Pohl J, et al
    Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
    Br J Cancer. 2021 Oct 6. pii: 10.1038/s41416-021-01553.
    PubMed     Abstract available

    September 2021
  2. ZHANG J, Nyvang D, Ibsen DB, Olsen A, et al
    Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study.
    Br J Cancer. 2021 Sep 30. pii: 10.1038/s41416-021-01556.
    PubMed     Abstract available

  3. BRETAGNE JF, Carlo A, Piette C, Rousseau C, et al
    Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
    Br J Cancer. 2021 Sep 12. pii: 10.1038/s41416-021-01546.
    PubMed     Abstract available

    July 2021
  4. ZABOROWSKI AM, Winter DC, Lynch L
    The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review.
    Br J Cancer. 2021 Jul 23. pii: 10.1038/s41416-021-01475.
    PubMed     Abstract available

  5. FURTADO FS, Suarez-Weiss KE, Vangel M, Clark JW, et al
    Clinical impact of PET/MRI in oligometastatic colorectal cancer.
    Br J Cancer. 2021 Jul 19. pii: 10.1038/s41416-021-01494.
    PubMed     Abstract available

  6. ZOLTICK ES, Smith-Warner SA, Yuan C, Wang M, et al
    Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival.
    Br J Cancer. 2021 Jul 15. pii: 10.1038/s41416-021-01487.
    PubMed     Abstract available

  7. TEN HOORN S, Sommeijer DW, Elliott F, Fisher D, et al
    Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01477.
    PubMed     Abstract available

  8. WANG X, Liu Q, Halfdanarson OO, Zoega H, et al
    Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01480.
    PubMed     Abstract available

  9. MORETTO R, Rossini D, Conca V, Lonardi S, et al
    CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01483.
    PubMed     Abstract available

  10. HUA X, Kratz M, Malen RC, Dai JY, et al
    Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
    Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01458.
    PubMed     Abstract available

    June 2021
  11. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    PubMed     Abstract available

  12. LIN M, Fang Y, Li Z, Li Y, et al
    S100P contributes to promoter demethylation and transcriptional activation of SLC2A5 to promote metastasis in colorectal cancer.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01306.
    PubMed     Abstract available

  13. GUO F, De Brabander I, Francart J, Candeur M, et al
    Correction: Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Br J Cancer. 2021 Jun 28. pii: 10.1038/s41416-021-01468.

  14. SEFRIOUI D, Beaussire L, Gillibert A, Blanchard F, et al
    CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Br J Cancer. 2021 Jun 10. pii: 10.1038/s41416-021-01431.
    PubMed     Abstract available

    May 2021
  15. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Correction: Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01426.

  16. SALVIANTI F, Gelmini S, Mancini I, Pazzagli M, et al
    Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01399.
    PubMed     Abstract available

  17. FRIEND T, Stebbing J
    Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01397.
    PubMed     Abstract available

    April 2021
  18. CHEN KH, Lin LI, Yuan CT, Tseng LH, et al
    Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01300.
    PubMed     Abstract available

  19. LUND CM, Vistisen KK, Olsen AP, Bardal P, et al
    The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO).
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01367.
    PubMed     Abstract available

  20. KIM DW, Tan E, Zhou JM, Schell MJ, et al
    A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01368.
    PubMed     Abstract available

  21. BAXTER MA, Murphy J, Cameron D, Jordan J, et al
    The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.
    Br J Cancer. 2021;124:1353-1356.
    PubMed     Abstract available

  22. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    PubMed     Abstract available

  23. THOMSON A, Bento DFC, Scurr MJ, Smart K, et al
    Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells.
    Br J Cancer. 2021;124:1552-1555.
    PubMed     Abstract available

    March 2021
  24. FEARON DT, Janowitz T
    AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    Br J Cancer. 2021 Mar 26. pii: 10.1038/s41416-021-01315.
    PubMed     Abstract available

  25. GOLDER AM, McMillan DC, Park JH, Mansouri D, et al
    The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01308.
    PubMed     Abstract available

  26. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01318.
    PubMed     Abstract available

  27. ROSENDAHL HUBER A, Pleguezuelos-Manzano C, Puschhof J
    A bacterial mutational footprint in colorectal cancer genomes.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01273.
    PubMed     Abstract available

  28. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available

  29. YAEGASHI M, Iwaya T, Sasaki N, Fujita M, et al
    Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
    Br J Cancer. 2021 Mar 3. pii: 10.1038/s41416-021-01266.
    PubMed     Abstract available

  30. NIMPTSCH K, Lee DH, Zhang X, Song M, et al
    Dairy intake during adolescence and risk of colorectal adenoma later in life.
    Br J Cancer. 2021;124:1160-1168.
    PubMed     Abstract available

    February 2021
  31. SHANG Y, Zhang X, Lu L, Jiang K, et al
    Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01272.
    PubMed     Abstract available

  32. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available

  33. PINTO-FERNANDEZ A, Salio M, Partridge T, Chen J, et al
    Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.
    Br J Cancer. 2021;124:817-830.
    PubMed     Abstract available

    January 2021
  34. ZHANG X, Theodoratou E, Li X, Farrington SM, et al
    Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2021 Jan 29. pii: 10.1038/s41416-020-01236.
    PubMed     Abstract available

  35. BAILEY SER, Abel GA, Atkins A, Byford R, et al
    Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England.
    Br J Cancer. 2021 Jan 19. pii: 10.1038/s41416-020-01221.
    PubMed     Abstract available

  36. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01222.
    PubMed     Abstract available

  37. CULLIFORD R, Cornish AJ, Law PJ, Farrington SM, et al
    Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01211.
    PubMed     Abstract available

  38. BRAGAGNOLI AC, Araujo RLC, Ferraz MW, Dos Santos LV, et al
    Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01208.
    PubMed     Abstract available

    December 2020
  39. LOUGHREY MB, Fisher NC, McCooey AJ, Dunne PD, et al
    Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes".
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01213.

  40. YASUI K, Shida D, Nakamura Y, Ahiko Y, et al
    Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01189.
    PubMed     Abstract available

  41. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.

  42. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.

    November 2020
  43. YU J, Li S, Xu Z, Guo J, et al
    CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and beta-catenin stabilisation via transactivation of PTEN expression.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01148.
    PubMed     Abstract available

  44. ALEXANDER PG, Roseweir AK, Pennel KAF, van Wyk HC, et al
    The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    Br J Cancer. 2020 Nov 23. pii: 10.1038/s41416-020-01168.
    PubMed     Abstract available

  45. JACOME AA, Vreeland TJ, Johnson B, Kawaguchi Y, et al
    The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Br J Cancer. 2020 Nov 19. pii: 10.1038/s41416-020-01169.
    PubMed     Abstract available

  46. HUIJBERTS SCFA, Boelens MC, Bernards R, Opdam FL, et al
    Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01147.
    PubMed     Abstract available

  47. HEINEMANN V, von Weikersthal LF, Decker T, Kiani A, et al
    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Br J Cancer. 2020 Nov 6. pii: 10.1038/s41416-020-01140.
    PubMed     Abstract available

  48. FANG Z, He M, Song M
    Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank.
    Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01143.
    PubMed     Abstract available

  49. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available

    October 2020
  50. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    PubMed     Abstract available

  51. WENSINK GE, Elferink MAG, May AM, Mol L, et al
    Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
    Br J Cancer. 2020 Oct 13. pii: 10.1038/s41416-020-01076.
    PubMed     Abstract available

  52. ROSSINI D, Lonardi S, Antoniotti C, Santini D, et al
    Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01089.
    PubMed     Abstract available

  53. HE F, Ju HQ, Ding Y, Jiang Z, et al
    Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.
    Br J Cancer. 2020;123:1244-1252.
    PubMed     Abstract available

    September 2020
  54. SIMIN J, Fornes R, Liu Q, Olsen RS, et al
    Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis.
    Br J Cancer. 2020 Sep 24. pii: 10.1038/s41416-020-01082.
    PubMed     Abstract available

  55. PAPE J, Magdeldin T, Stamati K, Nyga A, et al
    Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma.
    Br J Cancer. 2020;123:1178-1190.
    PubMed     Abstract available

  56. MURAHASHI S, Akiyoshi T, Sano T, Fukunaga Y, et al
    Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
    Br J Cancer. 2020;123:803-810.
    PubMed     Abstract available

    August 2020
  57. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available

    July 2020
  58. HOPPENER DJ, Nierop PMH, Hof J, Sideras K, et al
    Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis.
    Br J Cancer. 2020;123:196-206.
    PubMed     Abstract available

    June 2020
  59. ROOS VH, Kallenberg FGJ, van der Vlugt M, Bongers EJC, et al
    Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
    Br J Cancer. 2020;122:1865-1871.
    PubMed     Abstract available

    May 2020
  60. STREMITZER S, Vermeulen P, Graver S, Kockx M, et al
    Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
    Br J Cancer. 2020;122:1518-1524.
    PubMed     Abstract available

  61. QIN B, Zou S, Li K, Wang H, et al
    CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
    Br J Cancer. 2020;122:1673-1685.
    PubMed     Abstract available

    April 2020
  62. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available

  63. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available

    March 2020
  64. OTANDAULT A, Abraham JD, Al Amir Dache Z, Khalyfa A, et al
    Hypoxia differently modulates the release of mitochondrial and nuclear DNA.
    Br J Cancer. 2020;122:715-725.
    PubMed     Abstract available

    Whither Anal Cancer?
    Br J Cancer. 2020;122:733-734.
    PubMed     Abstract available

  66. SEKHAR H, Malcomson L, Kochhar R, Sperrin M, et al
    Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014).
    Br J Cancer. 2020;122:749-758.
    PubMed     Abstract available

  67. APARICIO T, Bennouna J, Le Malicot K, Boige V, et al
    Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
    Br J Cancer. 2020;122:957-962.
    PubMed     Abstract available

    February 2020
  68. VAN DE BEEK I, Glykofridis IE, Wolthuis RMF, Gille HJJP, et al
    No evidence for increased prevalence of colorectal carcinoma in 399 Dutch patients with Birt-Hogg-Dube syndrome.
    Br J Cancer. 2020;122:590-594.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.